Johnson & Johnson $JNJ Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 34.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 352,051 shares of the company’s stock after selling 187,772 shares during the quarter. Johnson & Johnson accounts for about 0.8% of QRG Capital Management Inc.’s holdings, making the stock its 17th biggest holding. QRG Capital Management Inc.’s holdings in Johnson & Johnson were worth $65,277,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $27,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson during the third quarter valued at $28,000. Semmax Financial Advisors Inc. lifted its position in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $35,000. Finally, Signature Resources Capital Management LLC boosted its position in Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Morgan Stanley increased their price target on Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Four research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $213.33.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $218.81 on Tuesday. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $220.11. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $527.18 billion, a PE ratio of 21.12, a price-to-earnings-growth ratio of 2.25 and a beta of 0.34. The business has a fifty day simple moving average of $206.43 and a 200-day simple moving average of $187.62.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer publicly praised J&J, highlighting its diversified businesses and steady cash flows — a high‑profile endorsement that can attract retail flows and support the stock. Jim Cramer Just Can’t Stop Praising Johnson & Johnson (JNJ)
• Positive Sentiment: J&J is featured in dividend-focused lists as a reliable income name, reinforcing demand from income investors given its yield and long dividend history. 3 Dividend Stocks to Own No Matter Where the Market Moves in 2026
• Positive Sentiment: Zacks highlighted J&J in its investment ideas feature, keeping the stock on investors’ radar as a large-cap healthcare pick. Zacks Investment Ideas feature highlights: Netflix, Intel and Johnson & Johnson
• Neutral Sentiment: Benzinga flags a “$10 billion test” in J&J’s 2026 outlook — management’s guidance and 2026 execution will be pivotal in the Q4 print and could swing sentiment either way. Johnson & Johnson’s $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4
• Neutral Sentiment: Analyst previews (Zacks, TipRanks, others) show mixed views: strong pharma and MedTech momentum but pressure from Stelara biosimilar competition and China headwinds — earnings will clarify the balance. Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
• Neutral Sentiment: Pre‑earnings pieces (TipRanks/MarketBeat) note analysts expect modest revenue growth into Q4; some investors are using hedged exposure strategies ahead of the release to limit risk. Is Johnson & Johnson (JNJ) Stock a Buy Ahead of Q4 Earnings?
• Negative Sentiment: Seeking Alpha warns that a sizable 2025 downgrade has tempered expectations; lowered growth assumptions can keep a lid on valuation and increase downside risk if guidance disappoints. Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)
• Negative Sentiment: Bank of America reiterated a Hold rating, signaling limited near‑term upside in analysts’ view and potentially constraining momentum from bullish headlines. Bank of America Securities Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.